Weight loss medications may lead to hair loss, as indicated by recent research findings. A study involving 50,000 individuals using weight loss injections like Wegovy and Mounjaro has highlighted a potential association with a rare side effect known as alopecia.
Reports of hair loss among users of appetite-suppressing medications have been escalating, prompting regulatory attention to investigate the root cause. Analysis of patient data from the University of Pennsylvania Health System in the US has seemingly confirmed the correlation, although the overall risk remains low.
According to research published in the British Medical Journal, patients taking weight loss drugs were 68% more likely to experience hair loss compared to those on different diabetes treatments. Experts suggest that this side effect could be attributed to sudden reductions in calorie intake and deficiencies in essential nutrients. The US Food and Drug Administration is currently conducting an inquiry into this potential adverse effect.
Dr. Yong Chen from the University of Pennsylvania highlighted, “Weight loss and alterations in nutritional status are established risk factors for telogen effluvium, a common form of non-scarring hair loss, which offers a plausible explanation for this connection.” While hair loss may not pose physical harm, its psychological impacts on self-esteem, quality of life, and adherence to treatment should not be disregarded.
The study has established a link with non-scarring alopecia, suggesting the possibility of hair regrowth as the hair follicles remain intact. However, it has not definitively confirmed the regrowth of lost hair.
Weekly injections such as Ozempic, Wegovy, and Mounjaro work by slowing digestion and curbing appetite through mimicking the hormone GLP-1, which regulates hunger and satiety. Despite their effectiveness in weight management, some experts, including Dr. Amir Khan, advocate for alternative weight loss strategies, emphasizing the importance of adequate sleep.
In the study, researchers compared individuals with type 2 diabetes using GLP-1 drugs with those on SGLT-2 inhibitors and DPP-4 inhibitors. After adjusting for various influencing factors, including age and weight, the research revealed that GLP-1 medications were associated with a 37% higher risk of alopecia compared to SGLT-2 inhibitors and a 68% higher risk compared to DPP-4 inhibitors.
Dr. Marie Spreckley, a weight management researcher at Cambridge University, noted, “Rapid weight loss can trigger temporary hair shedding, and deficiencies in vital nutrients like iron or zinc may also play a role.” While acknowledging the potential adverse effects, she emphasized the well-documented benefits of GLP-1 receptor agonists in improving glycemic control, reducing body weight, and lowering the risk of obesity-related complications.
Apart from hair loss, common side effects of GLP-1 drugs include vomiting and constipation. Therefore, personalized support from specialists is crucial to ensure sustained weight loss outcomes. While Mounjaro and Wegovy are prescribed by the NHS for weight loss purposes, Ozempic is primarily recommended for diabetes management.
